Paclitaxel (Taxol) in breast cancer

Hematol Oncol Clin North Am. 1994 Feb;8(1):121-40.


Paclitaxel (Taxol) is a diterpine plant compound that was isolated initially from the bark of the western yew tree, Taxus brevifolia, but can now be produced by semisynthesis from a renewable source. Paclitaxel is the first new agent in the past decade to have confirmed single agent activity in breast cancer in excess of 50%. A 28% response rate has been reported in doxorubicin-refractory patients. Ongoing studies include attempts to combine paclitaxel with other drugs used for breast cancer treatment and with radiation.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Clinical Trials as Topic
  • Drug Resistance
  • Female
  • Humans
  • Neoplasm Metastasis
  • Paclitaxel / therapeutic use*
  • Radiation-Sensitizing Agents / therapeutic use


  • Radiation-Sensitizing Agents
  • Paclitaxel